Alessandro Bonifazi Selected Research

Pain (Aches)

1/2023	Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders.
11/2019	The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Bonifazi Research Topics

Disease

7	Substance-Related Disorders (Drug Abuse) 01/2023 - 07/2015
4	Opioid-Related Disorders (Opiate Addiction) 10/2023 - 01/2016
4	Parkinson Disease (Parkinson's Disease) 11/2022 - 07/2015
3	Schizophrenia (Dementia Praecox) 01/2023 - 07/2015
2	Bulimia (Binge Eating) 01/2023 - 01/2019
2	Pain (Aches) 01/2023 - 11/2019
2	Dyskinesias (Dyskinesia) 11/2022 - 02/2019
2	Prostatic Neoplasms (Prostate Cancer) 04/2019 - 12/2014
2	Nervous System Diseases (Neurological Disorders) 01/2017 - 07/2015
1	Insulin Resistance 02/2024
1	Feeding and Eating Disorders (Eating Disorder) 01/2023
1	Obesity 01/2023
1	Mood Disorders (Mood Disorder) 01/2023
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2023
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 10/2021
1	Proteostasis Deficiencies 04/2021
1	Dystonia (Limb Dystonia) 04/2021
1	Parkinsonian Disorders (Parkinsonism) 04/2021
1	Motor Disorders 01/2021
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 10/2020
1	Alzheimer Disease (Alzheimer's Disease) 11/2019
1	Breast Neoplasms (Breast Cancer) 04/2019
1	Neuralgia (Stump Neuralgia) 01/2018
1	Neoplasms (Cancer) 01/2018
1	Restless Legs Syndrome (Restless Legs) 07/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2014
1	Xerostomia 08/2014

Drug/Important Bio-Agent (IBA)

8	LigandsIBA 01/2023 - 02/2019
5	Dopamine D3 ReceptorsIBA 10/2021 - 07/2015
3	Dopamine (Intropin)FDA LinkGeneric 01/2023 - 02/2019
3	Proteins (Proteins, Gene)FDA Link 04/2021 - 01/2018
3	1,4-dioxane (dioxane)IBA 04/2019 - 01/2019
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2019 - 12/2014
2	Dopamine D4 Receptors (Dopamine D4 Receptor)IBA 01/2023 - 01/2022
2	Cocaine (Cocaine HCl)IBA 01/2023 - 10/2020
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 04/2021 - 10/2020
2	5-HT1A Serotonin ReceptorIBA 04/2019 - 01/2019
2	N-Methylaspartate (NMDA)IBA 04/2019 - 01/2017
1	Bromocriptine (Parlodel)FDA LinkGeneric 02/2024
1	Glucose (Dextrose)FDA LinkGeneric 02/2024
1	Analgesics (Analgesic Drugs)IBA 10/2023
1	neuromedin UIBA 01/2023
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2023
1	cariprazineIBA 01/2023
1	Levodopa (L Dopa)FDA LinkGeneric 11/2022
1	noribogaineIBA 04/2021
1	Ibogaine (Endabuse)IBA 04/2021
1	Mutant Proteins (Protein, Mutant)IBA 04/2021
1	Dopamine Receptors (Dopamine Receptor)IBA 10/2020
1	R-VK4-40IBA 11/2019
1	Antineoplastic Agents (Antineoplastics)IBA 04/2019
1	spipethianeIBA 01/2019
1	Molecular Chaperones (Chaperone, Molecular)IBA 01/2018
1	eticloprideIBA 01/2016
1	Ion Channels (Ion Channel)IBA 12/2014
1	CalciumIBA 12/2014
1	ifenprodilIBA 12/2014
1	cevimeline (Evoxac)FDA Link 08/2014

Therapy/Procedure

2	Therapeutics 01/2021 - 11/2019
1	Self Administration (Administration, Self) 01/2023
1	Analgesia 10/2021